Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.28
AEGR's Cash to Debt is ranked lower than
90% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. AEGR: 0.28 )
Ranked among companies with meaningful Cash to Debt only.
AEGR' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 9.07 Max: No Debt
Current: 0.28
Equity to Asset 0.32
AEGR's Equity to Asset is ranked lower than
83% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AEGR: 0.32 )
Ranked among companies with meaningful Equity to Asset only.
AEGR' s Equity to Asset Range Over the Past 10 Years
Min: 0.32  Med: 0.79 Max: 0.87
Current: 0.32
0.32
0.87
F-Score: 5
Z-Score: -0.12
M-Score: 14.02
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -6.78
AEGR's Operating margin (%) is ranked higher than
66% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. AEGR: -6.78 )
Ranked among companies with meaningful Operating margin (%) only.
AEGR' s Operating margin (%) Range Over the Past 10 Years
Min: -128.43  Med: -72.65 Max: -16.86
Current: -6.78
-128.43
-16.86
Net-margin (%) -18.49
AEGR's Net-margin (%) is ranked higher than
61% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. AEGR: -18.49 )
Ranked among companies with meaningful Net-margin (%) only.
AEGR' s Net-margin (%) Range Over the Past 10 Years
Min: -130.51  Med: -77.69 Max: -24.87
Current: -18.49
-130.51
-24.87
ROE (%) -29.14
AEGR's ROE (%) is ranked higher than
51% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. AEGR: -29.14 )
Ranked among companies with meaningful ROE (%) only.
AEGR' s ROE (%) Range Over the Past 10 Years
Min: -105.89  Med: -76.69 Max: -28.82
Current: -29.14
-105.89
-28.82
ROA (%) -10.35
AEGR's ROA (%) is ranked higher than
66% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. AEGR: -10.35 )
Ranked among companies with meaningful ROA (%) only.
AEGR' s ROA (%) Range Over the Past 10 Years
Min: -189.06  Med: -61.99 Max: -14.07
Current: -10.35
-189.06
-14.07
ROC (Joel Greenblatt) (%) -54.95
AEGR's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. AEGR: -54.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AEGR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -88019.35  Med: -24512.59 Max: -897.06
Current: -54.95
-88019.35
-897.06
EBITDA Growth (3Y)(%) -21.90
AEGR's EBITDA Growth (3Y)(%) is ranked lower than
74% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. AEGR: -21.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AEGR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -12.40 Max: 20.3
Current: -21.9
0
20.3
EPS Growth (3Y)(%) -12.70
AEGR's EPS Growth (3Y)(%) is ranked lower than
60% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. AEGR: -12.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AEGR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -17.20 Max: 1.8
Current: -12.7
0
1.8
» AEGR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

AEGR Guru Trades in Q1 2015

Steven Cohen Sold Out
» More
Q2 2015

AEGR Guru Trades in Q2 2015

Jim Simons 159,575 sh (New)
» More
Q3 2015

AEGR Guru Trades in Q3 2015

Jim Simons 232,800 sh (+45.89%)
» More
Q4 2015

AEGR Guru Trades in Q4 2015

Jim Simons 125,900 sh (-45.92%)
» More
» Details

Insider Trades

Latest Guru Trades with AEGR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 66.67
AEGR's Forward P/E is ranked lower than
93% of the 343 Companies
in the Global Biotechnology industry.

( Industry Median: 16.58 vs. AEGR: 66.67 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.25
AEGR's P/B is ranked higher than
79% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 2.56 vs. AEGR: 1.25 )
Ranked among companies with meaningful P/B only.
AEGR' s P/B Range Over the Past 10 Years
Min: 1.25  Med: 7.68 Max: 24.68
Current: 1.25
1.25
24.68
P/S 0.73
AEGR's P/S is ranked higher than
98% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. AEGR: 0.73 )
Ranked among companies with meaningful P/S only.
AEGR' s P/S Range Over the Past 10 Years
Min: 0.72  Med: 8.24 Max: 1820.75
Current: 0.73
0.72
1820.75
PFCF 5.65
AEGR's PFCF is ranked higher than
95% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 28.77 vs. AEGR: 5.65 )
Ranked among companies with meaningful PFCF only.
AEGR' s PFCF Range Over the Past 10 Years
Min: 5.65  Med: 14.10 Max: 23.45
Current: 5.65
5.65
23.45
POCF 5.32
AEGR's POCF is ranked higher than
93% of the 380 Companies
in the Global Biotechnology industry.

( Industry Median: 27.35 vs. AEGR: 5.32 )
Ranked among companies with meaningful POCF only.
AEGR' s POCF Range Over the Past 10 Years
Min: 5.32  Med: 18.21 Max: 349.25
Current: 5.32
5.32
349.25
Current Ratio 2.43
AEGR's Current Ratio is ranked lower than
69% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. AEGR: 2.43 )
Ranked among companies with meaningful Current Ratio only.
AEGR' s Current Ratio Range Over the Past 10 Years
Min: 0.03  Med: 7.92 Max: 17.43
Current: 2.43
0.03
17.43
Quick Ratio 1.68
AEGR's Quick Ratio is ranked lower than
74% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. AEGR: 1.68 )
Ranked among companies with meaningful Quick Ratio only.
AEGR' s Quick Ratio Range Over the Past 10 Years
Min: 0.03  Med: 7.87 Max: 17.43
Current: 1.68
0.03
17.43
Days Inventory 298.99
AEGR's Days Inventory is ranked lower than
85% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. AEGR: 298.99 )
Ranked among companies with meaningful Days Inventory only.
AEGR' s Days Inventory Range Over the Past 10 Years
Min: 59.63  Med: 100.62 Max: 141.61
Current: 298.99
59.63
141.61
Days Sales Outstanding 27.41
AEGR's Days Sales Outstanding is ranked higher than
80% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. AEGR: 27.41 )
Ranked among companies with meaningful Days Sales Outstanding only.
AEGR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.47  Med: 48.20 Max: 56.93
Current: 27.41
39.47
56.93
Days Payable 88.38
AEGR's Days Payable is ranked higher than
65% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. AEGR: 88.38 )
Ranked among companies with meaningful Days Payable only.
AEGR' s Days Payable Range Over the Past 10 Years
Min: 246.71  Med: 273.86 Max: 301
Current: 88.38
246.71
301

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.09
AEGR's Price/Median PS Value is ranked higher than
97% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 0.87 vs. AEGR: 0.09 )
Ranked among companies with meaningful Price/Median PS Value only.
AEGR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.19  Med: 1.08 Max: 118.65
Current: 0.09
0.19
118.65
Price/Graham Number 0.52
AEGR's Price/Graham Number is ranked higher than
85% of the 407 Companies
in the Global Biotechnology industry.

( Industry Median: 2.23 vs. AEGR: 0.52 )
Ranked among companies with meaningful Price/Graham Number only.
AEGR' s Price/Graham Number Range Over the Past 10 Years
Min: 1.15  Med: 1.68 Max: 2.24
Current: 0.52
1.15
2.24
Earnings Yield (Greenblatt) (%) -5.02
AEGR's Earnings Yield (Greenblatt) (%) is ranked higher than
56% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. AEGR: -5.02 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AEGR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -7.7  Med: 0.00 Max: 0
Current: -5.02
-7.7
0

More Statistics

Revenue(Mil) $243
EPS $ -1.57
Beta2.08
Short Percentage of Float36.63%
52-Week Range $6.09 - 28.97
Shares Outstanding(Mil)28.94

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 199 228 280
EPS($) 0.15 1.07 1.97
EPS without NRI($) 0.15 1.07 1.97

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:KYE.Germany,
Aegerion Pharmaceuticals, Inc. was incorporated in February 2005. The Company is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Company currently operates in one business segment focusing on the development and commercialization of its product, lomitapide. The product, lomitapide, received marketing approval, under the brand name JUXTAPID (lomitapide) capsules ("JUXTAPID"). It is an adjunct to a low-fat diet and other lipid-lowering treatments, including low-density lipoprotein ("LDL") apheresis where available, to reduce low-density lipoprotein cholesterol ("LDL-C"), total cholesterol ("TC"), apolipoprotein B ("apo B") and non-high-density lipoprotein cholesterol ("non-HDL-C") in adult patients with homozygous familial hypercholesterolemia ("HoFH"). Lomitapide is also approved for the treatment of HoFH in Norway, Iceland, Mexico and Canada. The Company also sells lomitapide, on a named patient basis, in Brazil and in a limited number of other countries outside the U.S. and the EU where such sales are authorized based on the U.S. or the EU approval. The Company also launched JUXTAPID in the U.S. The Company relies on a contract manufacturer to produce drug substance for lomitapide and another contract manufacturer for drug product for its clinical trials and for commercial supplies. It distributes JUXTAPID through a specialty pharmacy that distributes JUXTAPID directly to patients and, under limited circumstances, to other purchasers. The lomitapide patent portfolio consists of five issued U.S. patents and issued patents in Europe, Canada, Israel, Australia, New Zealand and Japan and pending applications in the U.S., Australia, Japan, Canada, India and South Korea, all of which have been licensed in a specific field. The Company competes with Regeneron Pharmaceuticals, Inc., in collaboration with Sanofi, Roche Holding AG, Pfizer Inc., Amgen Inc., and Alnylam Pharmaceuticals, Inc. The Company's operations are subject to federal, state and local level, the EU and other countries extensively regulations.
» More Articles for NAS:AEGR

Headlines

Articles On GuruFocus.com
Gilead Sciences Releases Impressive Results for Hepatitis C Drug Nov 12 2014 
Weekly CEO Buys Highlight: APD, OCUL, CNMD, OPK, AEGR Aug 04 2014 
Weekly CEO Buys Highlight: GEO, TRUE, BANC, AEGR, CLMS Jun 02 2014 
Three CEOs Reporting Large Insider Buys May 22 2014 
Four CEOs Reporting Large Insider Buys May 09 2014 
100 Stocks at All-Time Highs | 60 Dividend Stocks Below the Results Feb 19 2013 
My 3 Favorite Dividend Stocks at All-Time-Highs | Stock List Dec 27 2012 
Weekly CFO Buys Highlight: RXN, XBKS, STAG, AEGR, PZG Apr 02 2012 

More From Other Websites
AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities Feb 11 2016
7:05 am Aegerion Pharma is reducing ~25% percent of its global workforce by end of 2Q16 Feb 11 2016
Aegerion Pharmaceuticals Announces Reduction in Workforce as Part of Cost Reduction Plan Feb 11 2016
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program Feb 10 2016
Aegerion Pharmaceuticals Announces Presentation at the Leerink Partners Global Healthcare Conference Feb 04 2016
AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Feb 03 2016
[$$] Six Biotechs to Like Right Now Jan 25 2016
5 Stocks Under $10 Set to Soar Jan 21 2016
Aegerion Provides Preliminary Sales View & Pipeline Updates Jan 12 2016
Aegerion Pharmaceuticals Reports Preliminary 2015 Net Product Sales and Other Business Updates Jan 11 2016
AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 11 2016
Aegerion Pharmaceuticals Reports Preliminary 2015 Net Product Sales and Other Business Updates Jan 11 2016
Aegerion Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference Jan 08 2016
Aegerion Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference Jan 08 2016
Aegerion Pharmaceuticals Appoints Mary Szela as Chief Executive Officer Jan 07 2016
Aegerion Pharmaceuticals Appoints Mary Szela as Chief Executive Officer Jan 07 2016
Biotechnology Equities at a Glance -- Chimerix, Vitae Pharma, Aegerion Pharma, and Compugen Jan 05 2016
Why Aegerion Pharmaceuticals (AEGR) Could Beat Earnings Estimates Again Dec 30 2015
Aegerion Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 22 2015
Pharmaceutical And LNG Stocks Are Driving The Market Higher Today Dec 21 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK